Skip to main content
Journal cover image

Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.

Publication ,  Journal Article
George, S; Yunus, F; Case, D; Yang, BB; Hackett, J; Shogan, JE; Meza, LA; Neumann, TA; Liang, BC
Published in: Leuk Lymphoma
October 2003

Twenty-nine patients with non-Hodgkin's lymphoma received a single subcutaneous injection of 6 mg pegfilgrastim approximately 24 h after the start of CHOP chemotherapy. The safety of pegfilgrastim in this patient population was determined by reports of adverse events. The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle. The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day. No apparent relationship between the duration of grade 4 neutropenia and body weight was observed. The median [quartiles] time to ANC recovery was 10 [9, 11] days. The incidence of febrile neutropenia was 11%. No unexpected adverse events were reported and no patient developed antibodies to pegfilgrastim. Serum concentration of pegfilgrastim reached a maximum (median [quartiles]) of 128 [58, 159] ng/ml at approximately 24 h after administration, and was followed by a second smaller peak (median [quartiles]) of 10.6 [3.0, 20.5] ng/ml at the time of the neutrophil nadir. After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.

Duke Scholars

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

October 2003

Volume

44

Issue

10

Start / End Page

1691 / 1696

Location

United States

Related Subject Headings

  • Vincristine
  • Treatment Outcome
  • Safety
  • Recombinant Proteins
  • Prednisone
  • Polyethylene Glycols
  • Neutrophils
  • Neutropenia
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, S., Yunus, F., Case, D., Yang, B. B., Hackett, J., Shogan, J. E., … Liang, B. C. (2003). Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma, 44(10), 1691–1696. https://doi.org/10.1080/1042819031000063462
George, S., F. Yunus, D. Case, B. B. Yang, J. Hackett, J. E. Shogan, L. A. Meza, T. A. Neumann, and B. C. Liang. “Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.Leuk Lymphoma 44, no. 10 (October 2003): 1691–96. https://doi.org/10.1080/1042819031000063462.
George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2003 Oct;44(10):1691–6.
George, S., et al. “Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma.Leuk Lymphoma, vol. 44, no. 10, Oct. 2003, pp. 1691–96. Pubmed, doi:10.1080/1042819031000063462.
George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, Meza LA, Neumann TA, Liang BC. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2003 Oct;44(10):1691–1696.
Journal cover image

Published In

Leuk Lymphoma

DOI

ISSN

1042-8194

Publication Date

October 2003

Volume

44

Issue

10

Start / End Page

1691 / 1696

Location

United States

Related Subject Headings

  • Vincristine
  • Treatment Outcome
  • Safety
  • Recombinant Proteins
  • Prednisone
  • Polyethylene Glycols
  • Neutrophils
  • Neutropenia
  • Middle Aged
  • Male